Quantitation of antigen-reactive T cells in peripheral blood by IFNγ-ELISPOT assay and chromium-release assay:: a four-centre comparative trial

被引:110
作者
Scheibenbogen, C
Romero, P
Rivoltini, L
Herr, W
Schmittel, A
Cerottini, JC
Woelfel, T
Eggermont, AMM
Keilholz, U
机构
[1] Free Univ Berlin, Klinikum Benjamin Franklin, Med Klin 3, Dept Med 3, D-12200 Berlin, Germany
[2] CHU Vaudois, Lausanne Branch, Ludwig Inst Canc Res, Div Clin Oncoimmunol, CH-1011 Lausanne, Switzerland
[3] Ist Nazl Tumori, I-20133 Milan, Italy
[4] Univ Mainz Klinikum, Dept Med 3, Mainz, Germany
[5] Dr Daniel Den Hoed Canc Ctr, NL-3008 AE Rotterdam, Netherlands
关键词
ELISPOT assay; limiting dilution assay; chromium-release assay;
D O I
10.1016/S0022-1759(00)00257-X
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
The ELISPOT assay is increasingly being used for the monitoring of the induction of antigen-reactive T cells in cancer vaccination trials. In order to evaluate the reliability of T cell frequency analysis with the ELISPOT assay, a comparative study was performed in four European laboratories. Six samples from healthy subjects were analyzed for the frequency of influenza-reactive CD8+ T cells in peripheral blood mononuclear cells (PBMC) by IFN gamma -ELISPOT assay. In addition, one laboratory determined cytotoxic T cell precursor (CTL) frequencies in these samples by limiting dilution chromium-release assay (LDA), and three laboratories performed a variant of the LDA, the multiple microculture assay (MMA). Consistent frequencies of influenza peptide-reactive T cells were obtained with the ELISPOT assay in all four laboratories. The numbers detected by ELISPOT assay correlated closely with those determined by LDA. In contrast, the frequencies obtained with the MMA differed considerably and showed Little correlation with the other two assays. This study shows that it is possible to use the ELISPOT assay tl, determine with reliability antigen-reactive T cells in a multicenter setting. We suggest that this assay may be suitable for monitoring cancer vaccine trials. (C) 2000 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:81 / 89
页数:9
相关论文
共 23 条
[1]   Phenotypic analysis of antigen-specific T lymphocytes [J].
Altman, JD ;
Moss, PAH ;
Goulder, PJR ;
Barouch, DH ;
McHeyzerWilliams, MG ;
Bell, JI ;
McMichael, AJ ;
Davis, MM .
SCIENCE, 1996, 274 (5284) :94-96
[2]  
BEDNAREK MA, 1991, J IMMUNOL, V147, P4047
[3]  
BRUNNER KT, 1968, IMMUNOLOGY, V14, P181
[4]   Phenotypic and functional separation of memory and effector human CD8(+) T cells [J].
Hamann, D ;
Baars, P ;
Rep, MHG ;
Hooibrink, B ;
KerkhofGarde, SR ;
Klein, MR ;
vanLier, RAW .
JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 186 (09) :1407-1418
[5]   Detection and quantification of blood-derived CD8(+) T lymphocytes secreting tumor necrosis factor alpha in response to HLA-A2.1-binding melanoma and viral peptide antigens [J].
Herr, W ;
Schneider, J ;
Lohse, AW ;
zumBuschenfelde, KHM ;
Wolfel, T .
JOURNAL OF IMMUNOLOGICAL METHODS, 1996, 191 (02) :131-142
[6]  
HERR W, 1997, ONKOLOGIE S1, V20, P12
[7]   Rapid effector function in CD8(+) memory T cells [J].
Lalvani, A ;
Brookes, R ;
Hambleton, S ;
Britton, WJ ;
Hill, AVS ;
McMichael, AJ .
JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 186 (06) :859-865
[8]   Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3 [J].
Marchand, M ;
Weynants, P ;
Rankin, E ;
Arienti, F ;
Belli, F ;
Parmiani, G ;
Cascinelli, N ;
Bourlond, A ;
Vanwijck, R ;
Humblet, Y ;
Canon, JL ;
Laurent, C ;
Naeyaert, JM ;
Plagne, R ;
Deraemaeker, R ;
Knuth, A ;
Jager, E ;
Brasseur, F ;
Herman, J ;
Coulie, PG ;
Boon, T .
INTERNATIONAL JOURNAL OF CANCER, 1995, 63 (06) :883-885
[9]   Differential anti-MART-1/MelanA CTL activity in peripheral blood of HLA-A2 melanoma patients in comparison to healthy donors: Evidence of in vivo priming by tumor cells [J].
Marincola, FM ;
Rivoltini, L ;
Salgaller, ML ;
Player, T ;
Rosenberg, SA .
JOURNAL OF IMMUNOTHERAPY, 1996, 19 (04) :266-277
[10]   The expanding universe of T-cell subsets: Th1, Th2 and more [J].
Mosmann, TR ;
Sad, S .
IMMUNOLOGY TODAY, 1996, 17 (03) :138-146